Trial Profile
Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferon
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Apr 2018
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CogniPlus
- Sponsors Bayer
- 23 May 2017 Status changed from active, no longer recruiting to completed.
- 09 Oct 2015 Results will be presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), as per Bayer media release.
- 21 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.